Zhejiang Jianfeng Group (600668) Fair Value & Analysis
Basic Materials · CN · Market cap 3.1B CNY
Fair value as of: Jun 24, 2026
Analysis
Zhejiang Jianfeng Group (600668) currently trades at ¥7.11, while our model-based Fair Value estimate is ¥12.44 — implying the stock looks roughly 75.0% undervalued today. We read business quality at 89/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Zhejiang Jianfeng Group Co., Ltd. engages in the building materials and pharmaceuticals business in China. The company offers pharmaceutical products, including antibiotics, cardiovascular drugs, antidepressants, ophthalmic drugs, anti-tumor drugs, and infant medications. It is involved in investment in pharmaceutical and healthcare industries; manufacturing and sales of cement and cement concrete; production and sales of pharmaceutical intermediates; sales of pharmaceutical chemical raw materials; and import and export business; and other industrial investments. Zhejiang Jianfeng Group Co., Ltd. was incorporated in 1989 and is based in Jinhua, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Zhejiang Jianfeng Group (600668) undervalued?
What is the fair value of 600668?
What is the quality score of 600668?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.